View Future GrowthLee's Pharmaceutical Holdings 過去の業績過去 基準チェック /36Lee's Pharmaceutical Holdingsの収益は年間平均-43.2%の割合で減少していますが、 Pharmaceuticals業界の収益は年間 増加しています。収益は年間10.7% 1.3%割合で 増加しています。 Lee's Pharmaceutical Holdingsの自己資本利益率は3.5%であり、純利益率は6.8%です。主要情報-43.22%収益成長率-43.22%EPS成長率Pharmaceuticals 業界の成長5.95%収益成長率1.31%株主資本利益率3.53%ネット・マージン6.81%前回の決算情報30 Jun 2025最近の業績更新お知らせ • Mar 17Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2025 Results on Mar 30, 2026Lee's Pharmaceutical Holdings Limited announced that they will report fiscal year 2025 results on Mar 30, 2026お知らせ • Aug 15Lee's Pharmaceutical Holdings Limited to Report First Half, 2025 Results on Aug 26, 2025Lee's Pharmaceutical Holdings Limited announced that they will report first half, 2025 results on Aug 26, 2025お知らせ • Mar 12Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2024 Results on Mar 27, 2025Lee's Pharmaceutical Holdings Limited announced that they will report fiscal year 2024 results on Mar 27, 2025お知らせ • Aug 16Lee's Pharmaceutical Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024Lee's Pharmaceutical Holdings Limited announced that they will report first half, 2024 results on Aug 28, 2024お知らせ • Mar 15Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024Lee's Pharmaceutical Holdings Limited announced that they will report fiscal year 2023 results on Mar 26, 2024お知らせ • Aug 19Lee's Pharmaceutical Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023Lee's Pharmaceutical Holdings Limited announced that they will report first half, 2023 results on Aug 30, 2023すべての更新を表示Recent updatesお知らせ • Mar 30Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 21, 2026Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 21, 2026.お知らせ • Mar 17Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2025 Results on Mar 30, 2026Lee's Pharmaceutical Holdings Limited announced that they will report fiscal year 2025 results on Mar 30, 2026お知らせ • Dec 10Lee's Pharmaceutical Holdings Limited (SEHK:950) signed asset purchase agreement to acquire Assets relating to Alexza Business of Alexza Pharmaceuticals, Inc., for $15 million.Lee's Pharmaceutical Holdings Limited (SEHK:950) signed asset purchase agreement to acquire Assets relating to Alexza Business of Alexza Pharmaceuticals, Inc., for $15 million on December 8, 2025. A cash consideration of $10 million will be paid by Lee's Pharmaceutical Holdings Limited. Lee's Pharmaceutical Holdings Limited will pay an earnout/contingent payment of $5 million cash which will be paid on June 1, 2026.. As part of consideration, $15 million is paid towards assets of Assets relating to Alexza Business of Alexza Pharmaceuticals, Inc.,. Assets relating to Alexza Business of Alexza Pharmaceuticals, Inc., reported total common equity of $58.67 million as on December 31, 2024. The expected completion of the transaction is December 8, 2025 to January 21, 2026.お知らせ • Aug 15Lee's Pharmaceutical Holdings Limited to Report First Half, 2025 Results on Aug 26, 2025Lee's Pharmaceutical Holdings Limited announced that they will report first half, 2025 results on Aug 26, 2025お知らせ • Mar 27Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2025Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2025.お知らせ • Mar 12Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2024 Results on Mar 27, 2025Lee's Pharmaceutical Holdings Limited announced that they will report fiscal year 2024 results on Mar 27, 2025お知らせ • Aug 16Lee's Pharmaceutical Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024Lee's Pharmaceutical Holdings Limited announced that they will report first half, 2024 results on Aug 28, 2024お知らせ • Aug 02Lee's Pharmaceutical Holdings Limited Announces the First Patient Has Been Enrolled in A Phase I Clinical Trial to Receive Au409 At Queen Mary Hospital, Hong KongLee's Pharmaceutical Holdings Limited announced that on 15 July 2024, the first patient has been enrolled in a Phase I clinical trial to receive AU409 at Queen Mary Hospital, Hong Kong. This trial focuses on patients with advanced hepatocellular carcinoma who have previously failed standard first-line treatment. AU409 is a novel drug discovered and owned by Auransa Inc. ("A Phase I, Single-arm, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of AU409 Capsule in Advanced Hepatocellular Carcinoma Patients who failed Standard Treatment" is led by Principal Investigator Dr. Chi Leung Chiang, MD. The primary objectives are to determine the maximum tolerated dose and recommended Phase II dose, as well as to characterise the safety and tolerability of AU409. Secondary objectives include assessing the pharmacokinetics and preliminary anti-tumor activity of AU409. AU409 is a novel drug discovered and owned by Auransa Inc. ("Auransa"), and is manufactured by Zhaoke Pharmaceutical (Guangzhou) Limited, a wholly owned subsidiary of the Group, in compliance with the Good Manufacturing Practice regulations set by the U.S. Food and Drug Administration. This Phase I clinical trial marks the first-in-human study in Asia and is expected to conclude by the second quarter of 2025. The results of this study will be used for China's new drug registration purpose.お知らせ • Jul 02Lee's Pharmaceutical Holdings Limited Appoints Huang Zuie Chin as A Non-Executive DirectorThe board of directors of Lee's Pharmaceutical Holdings Limited announced that after considering the recommendation of the nomination committee of the Company, the Board has appointed Mr. Huang Zuie Chin as a non-executive Director with effect from 2 July 2024. Mr. Huang, aged 59, has over 35 years' experience in the life science and investment industry together with 20 years' experience in the pharmaceutical and biotech industry holding senior roles in business development, sales, marketing and research and development. In 2011, he joined Kleiner Perkins Caufield & Byers China as a managing partner and focuses on the firm's life science practice. He is also the founding managing partner of Panacea Healthcare Venture Capital, including Panacea Venture Healthcare Fund I, L.P., Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P., which are venture capitals focusing on investments in innovative and transformative early and growth stage healthcare and life sciences companies worldwide. Mr. Huang received a Master of Business Administration (MBA) from the Stanford Graduate School of Business and a Bachelor of Science degree in chemical engineering from the University of California, Berkeley. He is a non-executive director of Kindstar Globalgene Technology Inc., whose shares are listed on The Stock Exchange of Hong Kong Limited (the "Stock Exchange") (Stock Code: 9960) since 2012, and a director of Connect Biopharma Holdings Limited, a company whose shares are listed on Nasdaq Global Market since 2024. Between 2020 and 2023, he was an executive director of Auto Italia Holdings Limited, whose shares are listed on the Stock Exchange (Stock Code: 720). Furthermore, Mr. Huang was the chairman of the board of directors of Alaunos Therapeutics Inc., whose shares are listed on NASDAQ Global Select Market, between 2021 and 2023. He was also a director of CASI PHARMACEUTICALS, INC., whose shares are listed on NASDAQ, between 2013 and 2023 and the chairman of the board of Windtree Therapeutics Inc., a company whose shares are listed on NASDAQ between 2019 and 2023.お知らせ • Mar 27Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2024Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2024. Agenda: To consider and approve the final dividend in respect of the year ended 31 December 2023 of HK1.0 cent per share in an aggregate amount of HK$5,888,000; and to consider other matters.お知らせ • Mar 26Lee's Pharmaceutical Holdings Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2023, Payable on 17 June 2024Lee's Pharmaceutical Holdings Limited proposed ordinary final dividend of HKD 0.01 per share for the year ended 31 December 2023. Date of shareholders' approval is 22 May 2024. Ex-dividend date is 28 May 2024. Record date is 31 May 2024. Payment date is 17 June 2024.お知らせ • Mar 15Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024Lee's Pharmaceutical Holdings Limited announced that they will report fiscal year 2023 results on Mar 26, 2024お知らせ • Aug 31Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 04 October 2023Lee's Pharmaceutical Holdings Limited announced interim dividend of HKD 0.008 per share for the six months ended June 30, 2023. Ex-dividend date is 12 September 2023. Record date is 15 September 2023. Payment date is 04 October 2023.お知らせ • Aug 22+ 1 more updateLee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023Lee's Pharmaceutical Holdings Limited provided earnings guidance for the six months ended 30 June 2023. For the period, the Group is expected to record an unaudited net profit attributable to the Shareholders of between HKD 12 million and HKD 17 million for the six months ended 30 June 2023 as compared with approximately HKD 28 million recorded for the six months ended 30 June 2022.お知らせ • Aug 19Lee's Pharmaceutical Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023Lee's Pharmaceutical Holdings Limited announced that they will report first half, 2023 results on Aug 30, 2023お知らせ • May 18Lee's Pharmaceutical Holdings Limited Appoints Cheang Yee Wah, Eva as Independent Non-Executive DirectorLee's Pharmaceutical Holdings Limited approved to appoint Ms. Cheang Yee Wah, Eva as the independent non-executive director of the Company, at the AGM held on 17 May 2023.お知らせ • Jan 20Lee's Pharmaceutical Holdings Limited Announces Inclusion of Treprostinil Injection, Teglutik and Trittico in the National Reimbursement Drug ListLee's Pharmaceutical Holdings Limited announce that the Group's commercialised products, namely Treprostinil Injection, Teglutik® and Trittico® have been included for the first time into the updated National Reimbursement Drug List (the "NRDL") issued by the China National Healthcare Security Administration on 18 January 2023 and will be officially implemented from 1 March 2023. Together with the other 6 products in the list, a total of 9 products of the Group have been included in the updated NRDL. Among 111 products included for the first time in this updated NRDL, 7 of which are from rare disease area and the Group's Treprostinil Injecton and Teglutik® have taken up 2 places thereof. Together with Trittico®, the Group firmly believed that the newly inclusion of these specialty drugs into the updated NRDL will help the Group to further enhance the affordabilityand accessibility thereof among patients in rare disease and mental health areas.収支内訳Lee's Pharmaceutical Holdings の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:LPCU.F 収益、費用、利益 ( )HKD Millions日付収益収益G+A経費研究開発費30 Jun 251,436985819131 Mar 251,418955898831 Dec 241,400935968430 Sep 241,300785618330 Jun 241,199635268231 Mar 241,126405108931 Dec 231,053174949730 Sep 2398054727530 Jun 231,0963949510131 Mar 231,1653952013231 Dec 221,2335154516930 Sep 221,350-11971723030 Jun 221,331-14075324831 Mar 221,3081,96676625831 Dec 211,2661,98775424430 Sep 211,2752,17662624130 Jun 211,2442,18857424131 Mar 211,22713053422631 Dec 201,21712951920330 Sep 201,19916752217730 Jun 201,16818451214631 Mar 201,20911850814131 Dec 191,21912649115030 Sep 191,18530147117430 Jun 191,17733144216831 Mar 191,13939540315631 Dec 181,13841841115330 Sep 181,12624338012330 Jun 181,10123337711231 Mar 181,0642563939631 Dec 171,0092333718530 Sep 179812453487730 Jun 179552563477231 Mar 179302453487431 Dec 169302523516830 Sep 169112593376130 Jun 168942473325031 Mar 169172423484131 Dec 159222293693930 Sep 159762214153230 Jun 159902094353731 Mar 1597919142640質の高い収益: LPCU.FにはHK$26.2M } という大きな 一回限りの 損失があり、過去 12 か月の財務実績が30th June, 2025に影響を及ぼしています。利益率の向上: LPCU.Fの現在の純利益率 (6.8%)は、昨年(5.3%)よりも高くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: LPCU.Fの収益は過去 5 年間で年間43.2%減少しました。成長の加速: LPCU.Fの過去 1 年間の収益成長率 ( 55.1% ) は、5 年間の平均 ( 年間-43.2%を上回っています。収益対業界: LPCU.Fの過去 1 年間の収益成長率 ( 55.1% ) はPharmaceuticals業界-6%を上回りました。株主資本利益率高いROE: LPCU.Fの 自己資本利益率 ( 3.5% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/02/17 18:59終値2025/11/20 00:00収益2025/06/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Lee's Pharmaceutical Holdings Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関Chu WangCitigroup IncJun Zhou LiEverbright Securities Co. Ltd.Yue-Kwong LuiJefferies LLC3 その他のアナリストを表示
お知らせ • Mar 17Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2025 Results on Mar 30, 2026Lee's Pharmaceutical Holdings Limited announced that they will report fiscal year 2025 results on Mar 30, 2026
お知らせ • Aug 15Lee's Pharmaceutical Holdings Limited to Report First Half, 2025 Results on Aug 26, 2025Lee's Pharmaceutical Holdings Limited announced that they will report first half, 2025 results on Aug 26, 2025
お知らせ • Mar 12Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2024 Results on Mar 27, 2025Lee's Pharmaceutical Holdings Limited announced that they will report fiscal year 2024 results on Mar 27, 2025
お知らせ • Aug 16Lee's Pharmaceutical Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024Lee's Pharmaceutical Holdings Limited announced that they will report first half, 2024 results on Aug 28, 2024
お知らせ • Mar 15Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024Lee's Pharmaceutical Holdings Limited announced that they will report fiscal year 2023 results on Mar 26, 2024
お知らせ • Aug 19Lee's Pharmaceutical Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023Lee's Pharmaceutical Holdings Limited announced that they will report first half, 2023 results on Aug 30, 2023
お知らせ • Mar 30Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 21, 2026Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 21, 2026.
お知らせ • Mar 17Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2025 Results on Mar 30, 2026Lee's Pharmaceutical Holdings Limited announced that they will report fiscal year 2025 results on Mar 30, 2026
お知らせ • Dec 10Lee's Pharmaceutical Holdings Limited (SEHK:950) signed asset purchase agreement to acquire Assets relating to Alexza Business of Alexza Pharmaceuticals, Inc., for $15 million.Lee's Pharmaceutical Holdings Limited (SEHK:950) signed asset purchase agreement to acquire Assets relating to Alexza Business of Alexza Pharmaceuticals, Inc., for $15 million on December 8, 2025. A cash consideration of $10 million will be paid by Lee's Pharmaceutical Holdings Limited. Lee's Pharmaceutical Holdings Limited will pay an earnout/contingent payment of $5 million cash which will be paid on June 1, 2026.. As part of consideration, $15 million is paid towards assets of Assets relating to Alexza Business of Alexza Pharmaceuticals, Inc.,. Assets relating to Alexza Business of Alexza Pharmaceuticals, Inc., reported total common equity of $58.67 million as on December 31, 2024. The expected completion of the transaction is December 8, 2025 to January 21, 2026.
お知らせ • Aug 15Lee's Pharmaceutical Holdings Limited to Report First Half, 2025 Results on Aug 26, 2025Lee's Pharmaceutical Holdings Limited announced that they will report first half, 2025 results on Aug 26, 2025
お知らせ • Mar 27Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2025Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2025.
お知らせ • Mar 12Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2024 Results on Mar 27, 2025Lee's Pharmaceutical Holdings Limited announced that they will report fiscal year 2024 results on Mar 27, 2025
お知らせ • Aug 16Lee's Pharmaceutical Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024Lee's Pharmaceutical Holdings Limited announced that they will report first half, 2024 results on Aug 28, 2024
お知らせ • Aug 02Lee's Pharmaceutical Holdings Limited Announces the First Patient Has Been Enrolled in A Phase I Clinical Trial to Receive Au409 At Queen Mary Hospital, Hong KongLee's Pharmaceutical Holdings Limited announced that on 15 July 2024, the first patient has been enrolled in a Phase I clinical trial to receive AU409 at Queen Mary Hospital, Hong Kong. This trial focuses on patients with advanced hepatocellular carcinoma who have previously failed standard first-line treatment. AU409 is a novel drug discovered and owned by Auransa Inc. ("A Phase I, Single-arm, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of AU409 Capsule in Advanced Hepatocellular Carcinoma Patients who failed Standard Treatment" is led by Principal Investigator Dr. Chi Leung Chiang, MD. The primary objectives are to determine the maximum tolerated dose and recommended Phase II dose, as well as to characterise the safety and tolerability of AU409. Secondary objectives include assessing the pharmacokinetics and preliminary anti-tumor activity of AU409. AU409 is a novel drug discovered and owned by Auransa Inc. ("Auransa"), and is manufactured by Zhaoke Pharmaceutical (Guangzhou) Limited, a wholly owned subsidiary of the Group, in compliance with the Good Manufacturing Practice regulations set by the U.S. Food and Drug Administration. This Phase I clinical trial marks the first-in-human study in Asia and is expected to conclude by the second quarter of 2025. The results of this study will be used for China's new drug registration purpose.
お知らせ • Jul 02Lee's Pharmaceutical Holdings Limited Appoints Huang Zuie Chin as A Non-Executive DirectorThe board of directors of Lee's Pharmaceutical Holdings Limited announced that after considering the recommendation of the nomination committee of the Company, the Board has appointed Mr. Huang Zuie Chin as a non-executive Director with effect from 2 July 2024. Mr. Huang, aged 59, has over 35 years' experience in the life science and investment industry together with 20 years' experience in the pharmaceutical and biotech industry holding senior roles in business development, sales, marketing and research and development. In 2011, he joined Kleiner Perkins Caufield & Byers China as a managing partner and focuses on the firm's life science practice. He is also the founding managing partner of Panacea Healthcare Venture Capital, including Panacea Venture Healthcare Fund I, L.P., Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P., which are venture capitals focusing on investments in innovative and transformative early and growth stage healthcare and life sciences companies worldwide. Mr. Huang received a Master of Business Administration (MBA) from the Stanford Graduate School of Business and a Bachelor of Science degree in chemical engineering from the University of California, Berkeley. He is a non-executive director of Kindstar Globalgene Technology Inc., whose shares are listed on The Stock Exchange of Hong Kong Limited (the "Stock Exchange") (Stock Code: 9960) since 2012, and a director of Connect Biopharma Holdings Limited, a company whose shares are listed on Nasdaq Global Market since 2024. Between 2020 and 2023, he was an executive director of Auto Italia Holdings Limited, whose shares are listed on the Stock Exchange (Stock Code: 720). Furthermore, Mr. Huang was the chairman of the board of directors of Alaunos Therapeutics Inc., whose shares are listed on NASDAQ Global Select Market, between 2021 and 2023. He was also a director of CASI PHARMACEUTICALS, INC., whose shares are listed on NASDAQ, between 2013 and 2023 and the chairman of the board of Windtree Therapeutics Inc., a company whose shares are listed on NASDAQ between 2019 and 2023.
お知らせ • Mar 27Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2024Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2024. Agenda: To consider and approve the final dividend in respect of the year ended 31 December 2023 of HK1.0 cent per share in an aggregate amount of HK$5,888,000; and to consider other matters.
お知らせ • Mar 26Lee's Pharmaceutical Holdings Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2023, Payable on 17 June 2024Lee's Pharmaceutical Holdings Limited proposed ordinary final dividend of HKD 0.01 per share for the year ended 31 December 2023. Date of shareholders' approval is 22 May 2024. Ex-dividend date is 28 May 2024. Record date is 31 May 2024. Payment date is 17 June 2024.
お知らせ • Mar 15Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024Lee's Pharmaceutical Holdings Limited announced that they will report fiscal year 2023 results on Mar 26, 2024
お知らせ • Aug 31Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 04 October 2023Lee's Pharmaceutical Holdings Limited announced interim dividend of HKD 0.008 per share for the six months ended June 30, 2023. Ex-dividend date is 12 September 2023. Record date is 15 September 2023. Payment date is 04 October 2023.
お知らせ • Aug 22+ 1 more updateLee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023Lee's Pharmaceutical Holdings Limited provided earnings guidance for the six months ended 30 June 2023. For the period, the Group is expected to record an unaudited net profit attributable to the Shareholders of between HKD 12 million and HKD 17 million for the six months ended 30 June 2023 as compared with approximately HKD 28 million recorded for the six months ended 30 June 2022.
お知らせ • Aug 19Lee's Pharmaceutical Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023Lee's Pharmaceutical Holdings Limited announced that they will report first half, 2023 results on Aug 30, 2023
お知らせ • May 18Lee's Pharmaceutical Holdings Limited Appoints Cheang Yee Wah, Eva as Independent Non-Executive DirectorLee's Pharmaceutical Holdings Limited approved to appoint Ms. Cheang Yee Wah, Eva as the independent non-executive director of the Company, at the AGM held on 17 May 2023.
お知らせ • Jan 20Lee's Pharmaceutical Holdings Limited Announces Inclusion of Treprostinil Injection, Teglutik and Trittico in the National Reimbursement Drug ListLee's Pharmaceutical Holdings Limited announce that the Group's commercialised products, namely Treprostinil Injection, Teglutik® and Trittico® have been included for the first time into the updated National Reimbursement Drug List (the "NRDL") issued by the China National Healthcare Security Administration on 18 January 2023 and will be officially implemented from 1 March 2023. Together with the other 6 products in the list, a total of 9 products of the Group have been included in the updated NRDL. Among 111 products included for the first time in this updated NRDL, 7 of which are from rare disease area and the Group's Treprostinil Injecton and Teglutik® have taken up 2 places thereof. Together with Trittico®, the Group firmly believed that the newly inclusion of these specialty drugs into the updated NRDL will help the Group to further enhance the affordabilityand accessibility thereof among patients in rare disease and mental health areas.